department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

darbepoetin alfa · pharmadog

pharmadog
drugs
darbepoetin alfa

drug

patient view →

darbepoetin alfa

updated 2mo ago

by Institute of Liver and Biliary Sciences

community read0 votes

all catalysts(1)

phase 2 completion · 1

phase 2 completion

Institute of Liver and Biliary Sciences — darbepoetin alfa (Phase II Trial Completion)

darbepoetin alfa

News(0)

no news has mentioned this drug yet

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 4

tagHepatology2 co-mentions · 1 sources
drugicosapent ethyl1 co-mentions · 1 sources
companyInstitute of Liver and Biliary Sciences1 co-mentions · 1 sources
drugdarbepoetin alfa LA1 co-mentions · 1 sources

Trials studying darbepoetin alfa

phase3Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japancompletedn=323
phase3Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japancompletedn=304
phase3A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)not yet recruitingn=100
phase2Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESAactive not recruitingn=13
phase3Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)completedn=319
phase3Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysiscompletedn=838
phase3Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfacompletedn=616
phase2A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drugcompletedn=130

more trials →